Tissue Regenix Group (LSE:TRX) EBIT : £-0.42 Mil (TTM As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Tissue Regenix Group EBIT?

Tissue Regenix Group's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was £-0.25 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was £-0.42 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Tissue Regenix Group's annualized ROC % for the quarter that ended in Dec. 2023 was -0.93%. Tissue Regenix Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -3.18%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Tissue Regenix Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -0.80%.

Tissue Regenix Group EBIT Historical Data

The historical data trend for Tissue Regenix Group's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tissue Regenix Group EBIT Chart

Tissue Regenix Group Annual Data

Trend

Jan14

Jan15

Jan16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-7.19

-9.36

-3.35

-1.71

-0.42

Tissue Regenix Group Semi-Annual Data
	Jan14	Jul14	Jan15	Jul15	Jan16	Jul16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT	Get a 7-Day Free Trial															-1.73	-1.01	-0.69	-0.17	-0.25

Competitive Comparison of Tissue Regenix Group's EBIT

For the Biotechnology subindustry, Tissue Regenix Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tissue Regenix Group's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tissue Regenix Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Tissue Regenix Group's EV-to-EBIT falls into.

Tissue Regenix Group EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.42 Mil.

Tissue Regenix Group (LSE:TRX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Tissue Regenix Group's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-0.252 * ( 1 - -6.61% )	/	( (28.295	+	29.262)	/ 2 )
=	-0.2686572	/	28.7785
=	-0.93 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	35.591	-	4.077	-	( 3.219	-	max(0, 4.388	-	16.561	+	3.219	))
=	28.295

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	34.162	-	1.226	-	( 3.674	-	max(0, 3.741	-	15.081	+	3.674	))
=	29.262

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Tissue Regenix Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-0.494	/	( ( (7.048 + max(9.265, 0))	+	(7.124 + max(7.656, 0)) )	/	2 )
=	-0.494	/	( ( 16.313	+	14.78 )	/	2 )
=	-0.494	/	15.5465
=	-3.18 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(4.232	+	8.996	+	0.114)	-	(4.077	+	0	+	0)
=	9.265

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(2.391	+	8.183	+	0.316)	-	(1.226	+	0	+	2.008)
=	7.656

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Tissue Regenix Group's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-0.42	/	52.420
	=	-0.80 %

Tissue Regenix Group EBIT Related Terms

Thank you for viewing the detailed overview of Tissue Regenix Group's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Tissue Regenix Group (LSE:TRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tissue Regenix Group PLC (LSE:TRX) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

LSW:Germany

Address

Lotherton Way, Unit 3, Phoenix Court, Garforth, GBR, LS25 2GY

Website

https://www.tissueregenix.com

Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.